Released : Jan 06, 2017 11:00
Director Declaration January 6, 2017 - Shire plc (LSE: SHP, NASDAQ: SHPG) (the 'Company') announces that Ian Clark, Non-Executive Director of the Company, was appointed to the Board of Directors of Kite Pharma, Inc. on January 5, 2017. This notification is to satisfy the Company's obligations under LR 9.6.14R of the UK Listing Rules. Oliver Strawbridge Senior Assistant Company Secretary For further information please contact: Investor Relations Ian Karp ikarp@shire.com +1 781 482 9018 Robert Coates rcoates@shire.com +44 1256 894874 Media Lisa Adler lisa.adler@shire.com +1 617 588 8607 Debbi Ford debbi.ford@shire.com +1 617 949 9083 NOTES TO EDITORS About Shire Shire is the leading global biotechnology company focused on serving people with rare diseases and other highly specialized conditions. We strive to develop best-in-class products, many of which are available in more than 100 countries, across core therapeutic areas including Hematology, Immunology, Neuroscience, Ophthalmics, Lysosomal Storage Disorders, Gastrointestinal / Internal Medicine / Endocrine and Hereditary Angioedema; and a growing franchise in Oncology. Our employees come to work every day with a shared mission: to develop and deliver breakthrough therapies for the hundreds of millions of people in the world affected by rare diseases and other high-need conditions, and who lack effective therapies to live their lives to the fullest.
www.shire.com
Shire plc published this content on 06 January 2017 and is solely responsible for the information contained herein.
Distributed by Public, unedited and unaltered, on 06 January 2017 11:07:05 UTC.
Original documenthttp://otp.investis.com/clients/uk/shire/rns/regulatory-story.aspx?cid=1027&newsid=833663
Public permalinkhttp://www.publicnow.com/view/1AE66606E1B5F9630B2907F61907FBEE861868EF